Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

13.22
+0.71005.68%
Post-market: 13.220.00000.00%19:30 EDT
Volume:851.70K
Turnover:11.13M
Market Cap:609.77M
PE:16.73
High:13.43
Open:12.53
Low:12.29
Close:12.51
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:1.01
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7900
EPS(LYR):1.80
ROE:16.40%
ROA:3.99%
PB:2.04
PE(LYR):7.34

Loading ...

Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member

Reuters
·
Aug 21

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Dow Jones
·
Aug 06

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

GlobeNewswire
·
Aug 06

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Aug 04

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

GlobeNewswire
·
Aug 03

Press Release: Radiopharm Theranostics Reports Business Update

Dow Jones
·
Jul 31

ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting

TIPRANKS
·
Jul 31

5 Microcap Software Stocks Expected to Soar by Triple Digits as the Companies' Sales Pop

Dow Jones
·
Jul 30

ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026

GlobeNewswire
·
Jul 23

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

GlobeNewswire
·
Jul 21

Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares

Reuters
·
Jul 01

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

GlobeNewswire
·
Jun 22

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

GlobeNewswire
·
Jun 22

Oddity Tech board expands share buyback distribution up to $200 million under Israeli Companies Law

Reuters
·
Jun 17

ODDITY Tech Sets July 29, 2026 AGM to Vote on Board, Auditor and Governance Matters

TIPRANKS
·
Jun 17

Oddity Tech announces annual shareholder meeting

Reuters
·
Jun 17

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

GlobeNewswire
·
Jun 15

Oddity Tech Unit to Repurchase $50 Million of Exchangeable Senior Notes

MT Newswires Live
·
Jun 12